Skip to content
OpenCapital
Get started

Coherus BioSciences CHRS Q4 2024 Annual earnings

Reported March 10, 2025 · After market close

Revenue$54.1MMiss by $5.9M
EPS-$0.28Miss by $0.18
Revenue estimate$60.0M
EPS estimate-$0.10

Next report

Aug 5, 2026 (In 1 week)
Revenue estimate$14.4M
EPS estimate-$0.12

Versus estimates

Revenue

Q1 2026$12.3MMiss by $1.9MQ4 2025$12.7MMiss by $1.2MQ3 2025$11.6MMiss by $2.5MQ2 2025$10.3MMiss by $1.7MQ1 2025$7.6MMiss by $53.4M
Q4 2024$54.1MMiss by $5.9M

Diluted EPS

Q1 2026-$0.25Beat by $0.01Q4 2025-$0.34Beat by $0.02Q3 2025-$0.33Miss by $0.01Q2 2025-$0.34Miss by $0.03Q1 2025-$0.35Miss by $0.04
Q4 2024-$0.28Miss by $0.18

Ask the moment Coherus BioSciences reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Coherus BioSciences report Q4 2024 earnings?
Coherus BioSciences (CHRS) reported Q4 2024 earnings on March 10, 2025 after market close.
What were Coherus BioSciences's Q4 2024 revenue and EPS?
Coherus BioSciences reported revenue of $54.1M and eps of $-0.28 for Q4 2024.
Did Coherus BioSciences beat estimates in Q4 2024?
Revenue missed the consensus estimate of $60.0M by $5.9M. EPS missed the consensus estimate of $-0.10 by $0.18.
Where can I find Coherus BioSciences's Q4 2024 SEC filings?
You can read the 10-K periodic report (0001558370-25-003126) directly on SEC EDGAR. The filing index links above go to sec.gov.